Novartis India share price today

Novartis India Ltd's share price was ₹1,722.40 at the close on 3 November 2026. It has been rising for 31 weeks. That is 17.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹769 and ₹2,393, and at that close it sat 59% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Novartis India Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 16 weeks in a row.

Over the last 11 years the share price moved +172% while the NIFTY 500 moved +257%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

1. Best operating margin in 15 quarters

   Operating margin was 34% in the June 2026 quarter, against 31% a year earlier.

2. Profit grew again in the June 2026 quarter

   Profit was ₹32 crore, +14.3% on a year earlier (₹28 crore), after 2 quarters of decline.

For April to June 2026 (the quarter ended 30 June 2026), Novartis India reported revenue of ₹104 crore, up 18.2% from ₹88.0 crore a year earlier, and a profit of ₹32.0 crore, up 14.3% from ₹28.0 crore.

Novartis India results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Novartis India closed at ₹1,722.40 on 3 November 2026, up 98.4% from ₹868.05 a year earlier (31 October 2025) and up 114.7% over five years. Its highest weekly close since February 2016 was ₹2,393.15 on 11 September 2026.

Novartis India share price: then and now

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

565 weekly closes from 26 February 2016 to 3 November 2026.

3 Nov 2026: Novartis India closed at ₹1,722.40, down 6.1% on the week and down 12.5% on the month. Results for April to June 2026: Revenue up 18.2% and profit up 14.3% on a year earlier.

Novartis India paid no dividend in the 12 months to 5 November 2026. The last was a dividend + special dividend of ₹47.50 a share, ex-date 20 July 2023.

Novartis India dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Novartis India Ltd paid out 66% of its profit as dividends in FY26, and it paid a dividend in 12 of its last 13 reported years. One of those years shows a negative figure because profit itself was negative.

From the NSE corporate-actions record, read 5 November 2026.

Novartis India is on one of our India lists: Pharma stocks.

Novartis India Ltd earned ₹32.0 Cr of net profit in the Jun 2026 quarter, +14.3% on the same quarter a year earlier. Full-year FY26 profit was ₹93.0 Cr. Over 10 years profit has grown −7.3% a year on average. That is 30.8% of the quarter's revenue. The same quarter a year earlier earned ₹28.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹93.0 Cr (−7.9% on the year before).

Why profit moved: revenue changed +18.2% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed −3.9% and revenue +5.6%. Profit is growing slower than sales: rising costs are taking part of the growth.

Novartis India Ltd reported ₹104 Cr of revenue in the Jun 2026 quarter, +18.2% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 10 years it has grown −6.5% a year on average. The last full year, FY26, came in at ₹354 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹371 Cr.

FY26 revenue was ₹354 Cr, −0.6% on the year before.

Recent pace: the last four quarters grew +5.6% on average, against −6.5% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +5.4%, against +4.9% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −4.9%, against +2.7% a year (rolling over).

Novartis India Ltd's operating margin was 34.0% in the Jun 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between −1.1% and 27.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +2.5 percentage points on the year while gross margin changed −0.2 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years, 84% of Novartis India Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹47.0 Cr of operating cash against ₹93.0 Cr of profit. After ₹0.0 Cr of spending on assets, ₹47.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 84% of profit came in as cash: the cash cycle got 17 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: it has been selling more assets than it buys. The next section shows those figures.

Novartis India Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 36 days in FY26, up from 19 days in FY21. Over the last 3 years it sold more assets than it bought, by ₹9.0 Cr. Customers take 38 days to pay, and stock sits for 98 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹354 Cr, each day of that cycle ties up about ₹1.0 Cr, so roughly ₹35.0 Cr is tied up in the business at any time.

FY26: customers took 38 days to pay and stock sat for 98 days, about 3.2 months of sales sitting as stock, for a full cycle of 36 days, longer than FY21's 19.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 98 days. Customers pay about 38 days after that. Suppliers are paid at 101 days. Together that makes the 36-day cycle.

Over the last 3 years, money from selling assets was ₹9.0 Cr more than it spent on new ones. Work still in progress is ₹0.0 Cr (FY26).

In short: assets are being sold, not built, so this cash is not going into new capacity.

Novartis India Ltd's P/E is 43.5×, near the high end of its own history: higher than 75% of past readings. Its usual P/E (the middle reading) is 30.7×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.